ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Pepperstone

Trade Now

Pepperstone
Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
AI Sign In Premium IconPremium Help Menu
S&P ASX 200
8,582.00
0.49%
S&P ASX All Technology
4,118.10
1.15%
Brent Oil
74.98
-0.15%
US Dollar vs AUD
1.58133
-0.12%
Bitcoin
96,733.03
0.12%
Pepperstone
Advertisement
Registration Strip Icon for pro Trade like a pro: Leverage real-time discussions and market-moving ideas to outperform.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ

  6. Precision BioSciences Inc (DTIL) Share Price

Precision BioSciences Inc

Precision BioSciences Inc (DTIL)

NASDAQ
5.06
-0.01
(-0.20%)
Closed 14 February 8:00AM
Delayed by 15 minutes
5.02
-0.04
(-0.79%)
After Hours: 10:55AM
Delayed by 15 minutes

Professional-Grade Tools, for Individual Investors.

Premium

Key stats and details

Current Price
5.02
Bid
5.02
Offer
5.20
Volume
58,295
4.93 Day's Range 5.15
3.61 52 Week Range 19.4299
Market Cap
38.509M
Previous Close
5.07
Open
5.15
Last Trade
20
@
5.02
Last Trade Time
Financial Volume
US$ 296,696
VWAP
5.0896
Average Volume (3m)
527,249
Shares Outstanding
7,671,059
Dividend Yield
-
PE Ratio
-0.63
Earnings Per Share (EPS)
-7.99
Revenue
48.73M
Net Profit
-61.32M

About Precision BioSciences Inc

Precision BioSciences Inc is a genome editing company dedicated to improving life through its genome editing platform, ARCUS. It leverages ARCUS in the development of its product candidates, which are designed to treat human diseases and provide food and agricultural solutions. The company's segment... Precision BioSciences Inc is a genome editing company dedicated to improving life through its genome editing platform, ARCUS. It leverages ARCUS in the development of its product candidates, which are designed to treat human diseases and provide food and agricultural solutions. The company's segments include Therapeutics and Food out of which the Therapeutics segment act as a key revenue driver for the firm. Show more

Sector
Biological Pds,ex Diagnstics
Industry
Biological Pds,ex Diagnstics
Website
www.precisionbiosciences.com
Headquarters
Wilmington, Delaware, USA
Founded
-
Precision BioSciences Inc is listed in the Biological Pds,ex Diagnstics sector of the NASDAQ with ticker DTIL. The last closing price for Precision BioSciences was US$5.07. Over the last year, Precision BioSciences shares have traded in a share price range of US$ 3.61 to US$ 19.4299.

Precision BioSciences currently has 7,671,059 shares in issue. The market capitalisation of Precision BioSciences is US$38.89 million. Precision BioSciences has a price to earnings ratio (PE ratio) of -0.63.

Ask ADVFN Intelligence (AI)

DTIL Latest News

More News

Form 8-K - Current report
Edgar (US Regulatory)
29 January 2025
DTIL (-0.20%)

Form 144 - Report of proposed sale of securities
Edgar (US Regulatory)
25 January 2025
DTIL (-0.20%)

Form 4 - Statement of changes in beneficial ownership of securities
Edgar (US Regulatory)
23 January 2025
DTIL (-0.20%)

Form 4 - Statement of changes in beneficial ownership of securities
Edgar (US Regulatory)
23 January 2025
DTIL (-0.20%)

Form 4 - Statement of changes in beneficial ownership of securities
Edgar (US Regulatory)
23 January 2025
DTIL (-0.20%)

Form 4 - Statement of changes in beneficial ownership of securities
Edgar (US Regulatory)
23 January 2025
DTIL (-0.20%)

Form 144 - Report of proposed sale of securities
Edgar (US Regulatory)
23 January 2025
DTIL (-0.20%)

Form 144 - Report of proposed sale of securities
Edgar (US Regulatory)
23 January 2025
DTIL (-0.20%)

Form 144 - Report of proposed sale of securities
Edgar (US Regulatory)
22 January 2025
DTIL (-0.20%)
PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
10.142.868852459024.885.124.6844594.85069335CS
4-0.29-5.461393596995.315.414.51352744.87016856CS
12-2.05-28.99575671857.077.653.615272495.51517217CS
26-3.82-43.21266968338.8411.093.612679495.99347991CS
52-6.35-55.848724714211.3719.42993.611799007.58504148CS
156-134.78-96.4091559371139.81473.6184701434.22715685CS
260-240.98-97.95934959352464983.61769645116.46847778CS

DTIL - Frequently Asked Questions (FAQ)

What is the current Precision BioSciences share price?
The current share price of Precision BioSciences is US$ 5.02
How many Precision BioSciences shares are in issue?
Precision BioSciences has 7,671,059 shares in issue
What is the market cap of Precision BioSciences?
The market capitalisation of Precision BioSciences is USD 38.89M
What is the 1 year trading range for Precision BioSciences share price?
Precision BioSciences has traded in the range of US$ 3.61 to US$ 19.4299 during the past year
What is the PE ratio of Precision BioSciences?
The price to earnings ratio of Precision BioSciences is -0.63
What is the cash to sales ratio of Precision BioSciences?
The cash to sales ratio of Precision BioSciences is 0.8
What is the reporting currency for Precision BioSciences?
Precision BioSciences reports financial results in USD
What is the latest annual turnover for Precision BioSciences?
The latest annual turnover of Precision BioSciences is USD 48.73M
What is the latest annual profit for Precision BioSciences?
The latest annual profit of Precision BioSciences is USD -61.32M
What is the registered address of Precision BioSciences?
The registered address for Precision BioSciences is CORPORATION TRUST CENTER, 1209 ORANGE STREET, WILMINGTON, DELAWARE, 19801
What is the Precision BioSciences website address?
The website address for Precision BioSciences is www.precisionbiosciences.com
Which industry sector does Precision BioSciences operate in?
Precision BioSciences operates in the BIOLOGICAL PDS,EX DIAGNSTICS sector

Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
GSATGlobalstar Inc
US$ 22.09
(5,422.50%)
914.19k
BSLKBolt Projects Holdings Inc
US$ 1.228
(302.62%)
273.1M
MBRXMoleculin Biotech Inc
US$ 1.27
(202.38%)
107.27M
CSAICloudastructure Inc
US$ 38.0312
(115.72%)
3.42M
PEVPhoenix Motor Inc
US$ 0.5101
(102.34%)
280M
RFACRF Acquisition Corporation
US$ 2.63
(-69.42%)
685.37k
RFACURF Acquisition Corporation
US$ 3.17
(-56.93%)
36.61k
HTLMHomesToLife Ltd
US$ 4.00
(-56.90%)
1.24M
DGLYDigital Ally Inc
US$ 0.0879
(-43.29%)
117.51M
TOIIWOncology Institute Inc
US$ 0.024
(-39.09%)
5.96k
MGOLMGO Global Inc
US$ 0.835
(82.99%)
739.4M
PEVPhoenix Motor Inc
US$ 0.5101
(102.34%)
280M
BSLKBolt Projects Holdings Inc
US$ 1.228
(302.62%)
273.1M
INTCIntel Corporation
US$ 24.13
(7.34%)
248.66M
NVDANVIDIA Corporation
US$ 135.29
(3.16%)
197.44M

DTIL Discussion

View Posts
tw0122 tw0122 1 month ago
Gene editing news $5 to $7s next 
👍️0
Monksdream Monksdream 2 months ago
DTIL under $5
👍️0
Monksdream Monksdream 5 months ago
DTIL under $10
👍️0
Monksdream Monksdream 7 months ago
DTIL under $10
👍️0
jondoeuk jondoeuk 8 months ago
I think they did, but there are still a lot of vampires sucking away at the (limited) revenue.
👍️0
Monksdream Monksdream 10 months ago
DTIL under $10
👍️0
NY1972 NY1972 10 months ago
Why they hired a Chief People Officer instead of of trimming head count? another GNCA IMO
👍️0
jondoeuk jondoeuk 10 months ago
Management can try and spin this as much as they want, but this is a failure https://www.businesswire.com/news/home/20240416117356/en/Precision-BioSciences-Announces-Return-of-Programs-and-Conclusion-of-Collaboration-with-Prevail-Therapeutics
👍️0
jondoeuk jondoeuk 10 months ago
If one of the companies that are developing off-the-shelf succeed, I don't see why any insurer will pay the price tag of an autologous therapy (assuming similar data/success). On paper, it should be easier than oncology.
👍️0
Monksdream Monksdream 11 months ago
DTIL 10Q due March 13
👍️0
jondoeuk jondoeuk 11 months ago
That didn't take long! https://www.businesswire.com/news/home/20240301968620/en/Precision-BioSciences-Announces-40.0-Million-Offering-of-Common-Stock-and-Warrants

Maybe things are going slower on the clinical front or no milestone payments are expected.
👍️0
rtrstock rtrstock 1 year ago
What do you mean an offering?
👍️0
surf1944 surf1944 1 year ago
Precision BioSciences, Inc. (DTIL) will effect a one-for-thirty (1-30) reverse split of its Common Stock. The reverse stock split will become effective on Wednesday, February 14, 2024. In conjunction with the reverse split, the CUSIP number will change to 74019P207

The 1 for 30 R/S will make it easy is come out with an offering in the next week or so.
👍️0
rtrstock rtrstock 1 year ago
1 for 30 not bad, but still will have to hold a long time to get my money back, if I ever do, averaged in at maybe 1.30, so uncertain what price will need to be after reverse split eventually to even break even. Wanting to hold long and make money eventually, but unsure if that's still possible.

I have 5100 shares, so that will be cut to practically nothing, it'd have to go to nearly 50.00 a share for me to make my money back?

Is this correct? Is basically everyone even the big investors like Lilly and Cargill losing big on this one?
👍️0
jondoeuk jondoeuk 1 year ago
Now there will be one. The BOD approved a 1-for-30 R/S. It will become effective at 5:00 p.m. ET on Feb 13. The uncertainty has been eliminated.
👍️0
rtrstock rtrstock 1 year ago
Guess I'll hold even if there is a R/S
👍️0
jondoeuk jondoeuk 1 year ago
I thought they would, but it seems to me that they want to allow the clock to run before they set a R/S. Looking at the filing, it leaves the effective date to the BOD's discretion. It also gives the them the discretion to abandon it. The company has until the 22nd of April for the stock price to attain what is needed, thereby keeping its listing.
👍️0
NY1972 NY1972 1 year ago
Side dish becomes the main course. High paid bio CEOs need another bait and switch.
👍️0
jondoeuk jondoeuk 1 year ago
Autoimmune diseases are clearly the next frontier for CAR-T/NK cell therapies, with numerous biotech and (big) pharma companies in the space https://finance.yahoo.com/news/precision-biosciences-completes-license-deal-120000510.html
👍️ 1
81vette 81vette 1 year ago
Res. Breakout,after hours could get fun
👍️ 1
81vette 81vette 1 year ago
Accumulation at nhod
👍️ 1
81vette 81vette 1 year ago
11th most newly watched ticker,do dd,others are
👍️0
81vette 81vette 1 year ago
The 2.5m buy, should open some eyes
👍️0
81vette 81vette 1 year ago
Death hour is over,mid day vol surge coming,this pennant has gotten pointy/pokey/stabby(technical terms lol)held strong with .4333 last low bounce,demand growing now,waiting for thru .44 to send it higher
👍️0
81vette 81vette 1 year ago
DTIL astronomical potential=greed/hold,tutes own 27%,insiders 21%,100M cash(no offerings),eps this year up 60%/sales past 5years up 102%(tells me sales have started and that explains tutes,I expect they buy more now) 27%below the sma200(so it’s got at least that much run room) target price 2.62, 198 employees,bullish chart since Oct 30th,could be some bashers because it is optionable/shortable,institutional could send this flying up,relative buying vol up 148Xs today ,shares available to short is dropping but still 3.5M(was 4.3m) overall I like that I can put this in my portfolio for long(or until chart breaks) and not have to watch it like a nail biting pump and dump,I have too many of those already lol
👍️0
rtrstock rtrstock 1 year ago
What indication of a RS is there? Or is it assumed?

This looks like a good buy to me, am I wrong?
👍️0
NY1972 NY1972 1 year ago
Plenty dead bios walking in this mkt. still handing out options like clock work.
👍️0
NY1972 NY1972 1 year ago
This bio is walking dead. Failure to let go the PhDs and CARTs a few years ago costed hundreds millions. ARCUS will be bought by IECure after the cash dries up.
👍️0
jondoeuk jondoeuk 1 year ago
Yes, but I think the R/S will happen.
👍️0
Sirpeter Sirpeter 1 year ago
There's still time
👍️0
jondoeuk jondoeuk 1 year ago
So, at 4:30pm the day before Thanksgiving, they announce a special meeting to vote on a R/S. It will take place on Thurs, Jan 18, '24, at 11:00 am, Eastern Time, at a ratio ranging from 1-for-10 and 1-for-30.
👍️0
Sirpeter Sirpeter 1 year ago
Moving up nicely...looks good
👍️0
knrorrel knrorrel 1 year ago
nice chart, bottom now and here, Now get the news out and let's see what happens, maybe we'll almost never see these low prices down here on the ground again.
imho
👍️0
knrorrel knrorrel 1 year ago
News Out, should running hard in good News
imho
👍️0
knrorrel knrorrel 1 year ago
a really nice $DTIL News https://ih.advfn.com/stock-market/NASDAQ/precision-biosciences-DTIL/stock-news/92484281/precision-biosciences-reports-third-quarter-2023-f


👍️0
rtrstock rtrstock 1 year ago
Well on stock twits they are saying there is no filed reverse split and that they are expecting an extension to be filed, so I hope you are right. I'm uncertain what all is going on, but I like what this company is doing with it's aspirations in medicine, so staying with it. Just accumulated more, lowered my average cost.
👍️0
konshe konshe 1 year ago
bottom rebound coming, time to buy.
👍️ 1
Monksdream Monksdream 1 year ago
DTIL new 52 week low
👍️0
Monksdream Monksdream 1 year ago
DTIL new 52 week low
👍️0
Monksdream Monksdream 1 year ago
DTIL new 52 wewek low
👍️0
NY1972 NY1972 1 year ago
DTIL founders never worried about cash until the meltdown. They hired too many PhDs, built fancy expensive labs with lots of promises. They never tried to trim the expenses to make sure there will be cash left for clinical trials. High burn and lots of GT bios spell doom for this bio.
👍️0
jondoeuk jondoeuk 1 year ago
I should have pointed out that companies are happening to develop small[er] nucleases. Here is one paper from Casebia Therapeutics, which is a joint venture between CRSP and BAYN https://www.nature.com/articles/s41467-021-24454-5

Also, in 2020, researchers led by Dr. Liu created a new base editor that could perform C-to-T conversion of DNA in mitochondria. However, it had limitations, not only being restricted to that conversion, but mostly limited a certain motif. This means that it could correct only 10% of confirmed pathogenic mitochondrial point mutations https://www.nature.com/articles/s41587-022-01256-8

Last year another novel base editor was created that could achieve A-to-G conversion. Being able to perform that could correct 43% of confirmed pathogenic mitochondrial point mutations https://www.cell.com/cell/fulltext/S0092-8674(22)00389-0

However, I don't see either base editor entering the clinic for a number of years.
👍️0
jondoeuk jondoeuk 1 year ago
Or it could end up like TRIL. ARCUS has some benefits over current CRISPR systems, manly its size, can edit the mitochondrial genome and IP is not a mess.
👍️0
NY1972 NY1972 1 year ago
IECure will buy the ARCUS IP when cash is 0 in 18 months.
👍️0
jondoeuk jondoeuk 1 year ago
Not the most productive use of its cash so far. The R&D Day could change that, but the market doesn't seem to think it.
👍️0
NY1972 NY1972 1 year ago
this is a homeless shelter for PhDs. Cash is not spent on patients. They hired a chief people officer to cut the pie.
👍️0
jondoeuk jondoeuk 1 year ago
The market did not find the recent announcement attractive https://www.businesswire.com/news/home/20230815091930/en/Precision-BioSciences-Completes-Strategic-Transaction-with-Imugene-for-Azer-Cel-in-Cancer

I think a reverse split is a possibility, especially after the announcement couldn't move the PPS. If that happens, will likely add fuel to any downward price pressure. Management don't seem the best. Now it's do or die with the in vivo programs.
👍️0
rtrstock rtrstock 1 year ago
That's what I'm afraid of, guess I'll just wait. Keep my shares.
👍️0
J-mak J-mak 1 year ago
In my opinon slim very very slim
👍️0
rtrstock rtrstock 1 year ago
What's the educated guess?

What's realistically possible by October date for pps to be more than $1.00
👍️0

Your Recent History

NASDAQ
DTIL
Precision BioSciences
AQSE
XSPX.GB
Deutsche Bank Luxembourg
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Australia
Company
Business
Popular
Get The App
App Store
Google Play

Support: +44 (0) 203 8794 460 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

© 2025 ADVFN PLC - All Rights Reserved

Go Ad-Free

Subscribe to Ad free and enjoy an ad-free experience

No Ads

Try Now

Keep the Ads